Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon.


Journal

Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 6 1 2019
medline: 13 7 2019
entrez: 6 1 2019
Statut: ppublish

Résumé

Thyrotropin (TSH)-secreting pituitary tumors are the rarest functioning pituitary tumors. Nonetheless, they are not infrequently plurihormonal, as they may express/secrete hormones made by other pituitary cells derived from the Pit-1 lineage such as growth hormone (GH), prolactin (PRL), and α-subunit (αSU). However, adrenocorticotropin (ACTH) or gonadotropin secretion by such a tumor is exceptional. Although double pituitary tumors are rare, they often combine ACTH and GH secretion. A 41-year-old presented almost 2 years after delivering her 10th child; she had thyrotoxicosis (goiter and palpitations) masquerading as autoimmune postpartum thyroiditis. She was still breastfeeding and amenorrheic. She proved to have TSH, GH, PRL, and ACTH hypersecretion. Imaging revealed an invasive pituitary macrotumor. She had stigmata neither of Cushing's disease nor of acromegaly. Prior to surgery, hormonal control was achieved for close to 1 year by combined octreotide and cabergoline treatment with significant shrinking of the tumor. Following surgery, pathology revealed a collision tumor; the dominant lesion was positive for GH, βTSH, βFSH, and αSU and expressed both Pit-1 and SF-1.The smaller lesion was a corticotroph tumor. We report an unusual plurihormonal tumor co-expressing Pit-1 and SF-1 along with hormones made by cells of both lineages. Its simultaneous occurrence adjacent to a corticotroph tumor raises questions regarding the pathogenesis of these tumors. We propose the possibility of a stem cell tumor with multiple lineage differentiation. We hypothesize that pregnancy might have played a permissive role in tumorigenesis.

Identifiants

pubmed: 30610567
doi: 10.1007/s12022-018-9562-3
pii: 10.1007/s12022-018-9562-3
doi:

Substances chimiques

Steroidogenic Factor 1 0
Transcription Factor Pit-1 0
Human Growth Hormone 12629-01-5
Prolactin 9002-62-4
Thyrotropin 9002-71-5

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-80

Références

Clin Endocrinol (Oxf). 2006 Oct;65(4):524-9
pubmed: 16984247
Eur J Endocrinol. 2007 Feb;156(2):203-16
pubmed: 17287410
J Neurosurg. 1991 Feb;74(2):243-7
pubmed: 1988594
Clin Neurol Neurosurg. 2011 Nov;113(9):810-2
pubmed: 21906866
J Korean Med Sci. 2014 Mar;29(3):405-10
pubmed: 24616591
J Neurosurg. 2014 Dec;121(6):1462-73
pubmed: 25237847
Pituitary. 2016 Apr;19(2):183-93
pubmed: 26689573
Front Endocrinol (Lausanne). 2016 Feb 01;7:1
pubmed: 26869991
Mol Neurobiol. 2017 Sep;54(7):4879-4895
pubmed: 27514754
Zh Vopr Neirokhir Im N N Burdenko. 2016;80(6):24-35
pubmed: 28139570
Pituitary. 2017 Dec;20(6):702-708
pubmed: 28766078
J Endocrinol. 2018 Jan;236(1):R1-R13
pubmed: 28855316
Neurol India. 2017 Sep-Oct;65(5):1162-1164
pubmed: 28879926
Mod Pathol. 2018 Jun;31(6):900-909
pubmed: 29434339
Endocr Pathol. 2018 Jun;29(2):130-136
pubmed: 29453601
World Neurosurg. 2018 Jun;114:e158-e164
pubmed: 29501516
Brain Tumor Pathol. 2018 Apr;35(2):51-56
pubmed: 29687298
Endocr Pract. 2018 Jun;24(6):580-588
pubmed: 29949434
Endocr Pathol. 2018 Dec;29(4):332-338
pubmed: 30215160
Mod Pathol. 2019 Apr;32(4):484-489
pubmed: 30390035
Acta Neurochir (Wien). 1996;138(8):1002-7
pubmed: 8890999

Auteurs

Karen M Tordjman (KM)

Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 64239, Tel Aviv, Israel. karent@tlvmc.gov.il.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. karent@tlvmc.gov.il.

Yona Greenman (Y)

Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, 6 Weizmann Street, 64239, Tel Aviv, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zvi Ram (Z)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Dov Hershkovitz (D)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Institute of Pathology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Orna Aizenstein (O)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Radiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

Ofra Ariel (O)

Maccabi Health Services, Tel Aviv, Israel.

Sylvia L Asa (SL)

Department of Pathology, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH